Reimbursement Listing in 2018-2019

• Japan’s First Biosimilars of Avastin, Nesp, Forteo Receive Listing
  November 27, 2019

• Astellas’ HIF-PH Inhibitor, Trintellix, Venclexta, and Many More OK’ed for Listing on Nov. 19
  November 13, 2019

• Keytruda to Get 17.5% Price Cut in February
  November 13, 2019

• Keytruda Faces Price Slash on Better-than-Expected Sales
  November 12, 2019

• Nippon Kayaku Skips September Listing for Lilly’s Portrazza
  August 29, 2019

• Tagrisso Gets 15% Re-Pricing, but Other EGFR Drugs Spared: Chuikyo
  August 29, 2019

• Rozlytrek, Onpattro and Many More to Join NHI Price List on Sept. 4
  August 28, 2019

• Gene Therapy Collategene Gets 600,000 Yen Price Tag, Peak Sales Put at 1.2 Billion Yen
  August 28, 2019

• Tagrisso to Face 15% Price Cut in November Because It Sold Too Well
  August 27, 2019

• Nesp Biosame Priced at 62.8-69.2% of Originator
  June 14, 2019

• Nesp Biosame to Join NHI Price List, Launch Due by September; Symbicort Generics, Teribone AG Skip Listing
  June 13, 2019

• As Kymriah Fetches Highest List Price, Policymakers Talk over Difficulty in Cell Therapy Pricing
  May 16, 2019

• Japan OKs Listing of Trelegy, Erleada, and More; GSK’s COPD Hopeful to Face Cost-Effectiveness Analysis
  May 15, 2019

• Kymriah Gets 33.5 Million Yen Price Tag, Peak Sales Put at 7.2 Billion Yen
  May 15, 2019

• Kymriah Likely to Fetch 33 Million Yen Price Tag, Collategene to Skip Listing
  May 14, 2019

• Kyowa to Skip May Listing for Enbrel Biosimilar, Codeveloper YL Biologics to Move Ahead
  April 11, 2019

• Gilead’s HIV Triplet Biktarvy to Join NHI Price List on April 3
  March 27, 2019

• Japan OKs Listing of Evenity, Tarlige, Epclusa, and More on Feb. 26
  February 20, 2019

• Stemirac Fetches 15 Million Yen Price Tag, Peak Sales Put at 3.7 Billion Yen
  February 20, 2019

• ViiV’s HIV Drug Juluca to Join NHI Price List on Dec. 12
  December 5, 2018

ページ